Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment

Transplant International

Volumn 27, Issue 4, 2014, Pages 371-382

  Ishida, Hideki ^a   Furusawa, Miyuki ^a   Shimizu, Tomokazu ^a   Nozaki, Taiji ^a   Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

acute antibody mediated rejection; anti HLA antibodies; B cell targeting protocol; B cell activating factor belonging to the tumor necrosis factor family; chronic antibody mediated rejection; de novo antibodies; desensitization protocol; graft loss; graft survival rate; renal transplantation; rituximab

Indexed keywords

BASILIXIMAB; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; BLOOD; DONOR; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; PREOPERATIVE PERIOD;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 84898985625     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12267     Document Type: Article

References (32)

1. Zhang Q, Liang LW, Gjertson DW, et al,. Development of posttransplant anti donor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591.
2. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al,. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
3. Terasaki PI, Ozawa M,. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
4. Hirai T, Kohei N, Omoto K, et al,. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody mediated rejection. Transpl Int 2012; 25: 925.
5. Ishida H, Tanabe K,. The evaluation of graft Irradiation as a method of preventing hemolysis after ABO-mismatched renal transplantation. Transpl Int 2002; 15: 421.
6. Ishida H, Miyamoto N, Tanabe K, et al,. Evaluation of immunosuppressive regimens in ABO-incompatible living related kidney transplantation-single center analysis-. Am J Transplant 2007; 7: 825.
7. Shimizu T, Tanabe K, Tokumoto T, et al,. Histopathological features of renal allograft biopsies in ABO minor mismatched kidney transplantation. Clin Transplant, 2004; 18 (Suppl. 11): 24.
8. Rozman P, Kosir A, Bohhinjec M,. Is the ABO-incompatibility a risk factor in bone marrow transplantation? Transpl Immunol 2005; 14: 159.
9. Yazer MH,. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol 2007; 14: 664.
10. Shirakawa H, Ishida H, Shimizu T, et al,. The low-dose of rituximab in ABO-incompatible kidney transplantation without splenectomy; a single center experience. Clin Transplant 2011; 25: 878.
11. Neha N, Neeraj S, Thomas S, et al,. Cross reactive Epitope Group antibodies in sensitized kidneys transplant recipients was associated with early acute Antibody Mediated Rejection. Transpl Immunol 2009; 20: 113.
12. Maniyyedi S, Colvin RB,. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11: 609.
13. Mahanty HD, Cherikh WS, Chanq GJ, Baxter-Lowe LA, Roberts JP,. Influence of pretransplant pregnancy on survival of renal allograft from living donors. Transplantation 2001; 72: 228.
14. Campos EF, Tedesco-Silva H, Machado PG,. Post-transplant anti-HLA ClassII antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
15. Leckman N, Terasaki PI, Budde K, et al,. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
16. Everly MJ, Rebellato LM, Maisch CE, et al,. Incidence and impact of de novo donor specific alloantibody in primary renal allografts. Transplantation 2013; 96: 410.
17. Wahrmann M, Exner M, Schillinger M, et al,. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6: 1033.
18. Taniguchi M, Rebellato LM, Cai J, et al,. Higher risk of kidney graft failure in the presence of anti-angiotensin type-1 receptor antibodies. Am J Transplant 2013; 13: 2577.
19. Tsuchiya T, Ishida H, Tanabe T, et al,. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation 2013; 96: 198.
20. Li X, Ishida H, Tanabe K, et al,. Poor graft outcome in recipients with de novo donor specific anti-HLA antibodies after living related kidney transplantation. Transpl Int 2008; 21: 1145.
21. Cooper JE, Gralla J, Cagle L, et al,. Inferior kidney allograft outcomes in patients with de novo DSA are due to acute rejection episodes. Transplantation 2011; 91: 1103.
22. DeVos JM, Gaber AO, Knight RJ, et al,. Donor specific HLA-DQ antibodies may contribute to poor graft outcomes after renal transplantation. Kidney Int 2012; 82: 598.
23. Loupy A, Suberbielle BC, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
24. Kohei N, Hirai T, Ishida H, et al,. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469.
25. Billing H, Rieger S, Susal C, et al,. IVIG and rituximab for treatment of chronic antibody mediated rejection; prospective study in pediatric renal transplantation with a 2 year follow-up. Transpl Int 2012; 25: 1165.
26. Hong Y, Kim HG, Choi SR, et al,. Effectiveness of rituximab and IVIG in renal transplant recipients with chronic antibody mediated rejection. Transplant Proc 2012; 44: 182.
27. Barnett AN, Hadianastassiou VG, Mamode N,. Rituximab in renal transplantation. Transpl Int 2013; 26: 563.
28. Aggarwal A, Pyle J, Hamilton J, Bhat G,. Low dose rituximab therapy for antibody mediated rejection in a highly sensitized heart transplant recipient. Tex Heart Inst J 2012; 39: 901.
29. Zachary AA, Lucas DP, Mongomery RA, et al,. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95: 701.
30. Pescovitz MD,. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859.
31. Clatworthy MR, Watson C, Plotnek G, et al,. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683.
32. Ishida H, Inui M, Furusawa M, et al,. Late-onset neutropenia after low dose rituximab treatment in living related kidney transplantation. Transpl Immunol 2013; 28: 93.